Press Announcements > FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation

Press Announcements > FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation

In case you missed it FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation - FDA approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease). This was the first drug granted approval under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, instituted to spur development of antibiotics for unmet medical needs. (September 28, 2018) FDA Fast Facts: Hurricane Michael Response Efforts (October 11, 2018) Statements from FDA Commissioner Scott Gottlieb, M.D.: FDA’s efforts to strengthen the agency’s medical device cybersecurity program as part of its mission to protect patients (October 1, 2018) Preparations for the upcoming flu season and vaccinations (September 27, 2018) You want to make a difference. FDA wants to hire you. Follow @FDAJobs on Twitter, or visitwww.fda.gov/jobs.